STAT Stitch Deep Dive Podcast Beyond The Bedside

STAT Stitch Deep Dive Podcast Beyond The Bedside

di Regular Guy

Corsi Scienza della vita

Stagione 6

MH | Psycho Assessment PRIMER

2. Critical Factors Influencing the Assessment Nurses must manage several variables that can compromise the accuracy of their data: Client Health Status: Pain, fatigue, or high anxiety severely limit participation. The nurse must prioritize addressing these acute physical or emotional needs before continuing the full assessment. Previous Experiences & Trust: Clients with past negative healthcare experiences or reluctance to seek treatment may minimize or maximize symptoms. The nurse's first priority is to establish a safe, trusting environment. Nurse’s Approach: A judgmental, defensive, or rushed attitude will cause clients to withhold sensitive information (e.g., domestic violence or substance use). The nurse must maintain a matter-of-fact, nonjudgmental tone. Safety & Environment: Conduct the interview in a private, quiet setting to minimize distractions. However, never choose an isolated room if the client has a history of threatening behavior; safety for both the nurse and client is always paramount. Communication Strategies: Begin with open-ended questions to gauge the client's perception. If the client exhibits psychotic thoughts, confusion, or cannot organize their thoughts, immediately switch to direct, closed-ended questions focusing on one specific behavior at a time. Phrasing matters: ask "What types of discipline do you use?" rather than "How often do you physically punish your child?" to prevent defensive dishonesty. Family Input: Obtaining input from family is valuable, but the client must give permission. The nurse should always try to assess the client in private if abuse or intimidation is suspected. 3. The 9 Must-Know Assessment Categories (The Organizing Framework) Nurses must systematically evaluate these nine areas to guide clinical judgment: History: Includes age, developmental stage, cultural beliefs, and family history. A family history of suicide, alcohol use disorder, or bipolar disorder represents a major safety risk factor. General Appearance & Motor Behavior: Observe hygiene, posture, eye contact, speech, and any unusual mannerisms. Mood & Affect: Assess the client's internal emotional state (mood) and outward facial expressions (affect). Thought Process & Content: Evaluate what they think (content) and how they think (process). This is where the nurse must systematically screen for dangerous cues like self-harm or suicidal urges. Sensorium & Intellectual Processes: Assess orientation, memory, confusion, concentration, abstract thinking, and abnormal sensory experiences. Judgment & Insight: Determine the client's decision-making ability (judgment) and their understanding of their own part in their current situation (insight). Self-Concept: Evaluate the client's personal view of their physical self and attributes. Roles & Relationships: Assess current life roles, relationship satisfaction, and their external support systems. Physiological & Self-Care: A crucial area focusing on sleep patterns, eating habits, medication adherence, and the client's ability to independently perform activities of daily living (ADLs).

MH | Grief and Loss PRIMER

Core Concepts of Loss and Grieving Grief is the subjective emotional response to loss, while grieving (bereavement) is the process of experiencing it, and mourning is the outward, culturally defined expression. Losses fundamentally disrupt Maslow’s hierarchy of human needs, threatening physiological integrity, safety, security, self-esteem, and self-actualization. The grieving process is highly dynamic and unique to each individual; it is never an orderly progression. Major Frameworks of Grieving Nurses utilize several key theories to understand the grief process: Kübler-Ross: Denial, anger, bargaining, depression, and acceptance. Bowlby: Numbness, emotional yearning, cognitive disorganization, and reorganization. Engel: Shock/disbelief, developing awareness, restitution, resolution, and recovery. Horowitz: Outcry, denial/intrusion, working through, and completion. The Five Dimensions of Grieving Effective nursing requires a holistic assessment of five human responses: Cognitive: Disruption of beliefs, questioning the loss to make sense of it, and carrying on internal dialogues to keep the lost one present. Emotional: Predominantly anger, sadness, anxiety, guilt, despair, and intense loneliness. Spiritual: Deep spiritual suffering, anger with God, or conversely, finding comfort and meaning through religious belief systems. Behavioral: Numbness, uncontrollable crying, irritability, searching behaviors, and potentially maladaptive responses like substance use or suicide attempts. Physiological: Insomnia, headaches, impaired appetite, weight loss, lack of energy, and profound changes in the immune and endocrine systems. High-Risk Types of Grief Disenfranchised Grief: Occurs when a loss cannot be openly acknowledged or socially supported. Examples include stigmatized deaths (execution), unacknowledged losses (pets, prenatal death, abortions), non-kin relationships, or grief experienced by healthcare workers. Complicated Grieving: A prolonged, intensely persistent response that interferes with daily life. Risk factors include low self-esteem, prior psychiatric disorders, ambivalent attachments, and sudden, violent, or multiple deaths. Hospital visitation restrictions heavily increase susceptibility to complicated grief. Nursing Assessment and Interventions Nurses must carefully evaluate three critical factors: adequate perception of the loss, adequate situational support, and adequate coping behaviors. Priority Safety Actions: Assess for suicidal ideation, self-harm risk, and severe depression. Key Interventions: Establish a psychologically safe environment using an attentive presence and active listening. Support adaptive denial, allowing the client to gradually adjust to the reality of the loss. Encourage the client to express all emotions without placation, review past coping strengths, and care for physical needs. Refer clients to Cognitive-Behavioral Grief Therapy (CBGT) for complicated grief. Nurses must also maintain self-awareness regarding personal loss to remain fully therapeutic.

MH | Anger and Hostility PRIMER

Core Concepts & Etiology Anger is a normal human emotion, but inappropriate expression leads to hostility (verbal intimidation) and physical aggression. Biologically, aggression is linked to low serotonin, elevated dopamine and norepinephrine, and limbic system damage. High-risk conditions include schizophrenia (especially with command hallucinations), bipolar disorder, substance intoxication, dementia, and personality disorders. "Acting out" is an immature defense mechanism where clients use physical actions rather than words to cope with feelings of powerlessness. The 5-Phase Aggression Cycle & Interventions Mastering this cycle is vital for clinical safety. Triggering: The client exhibits restlessness, pacing, anxiety, and a loud voice. Action: Approach calmly, convey empathy, encourage the verbal expression of feelings, offer PRN medications, and suggest moving to a quiet area. Escalation: Behavior rapidly escalates (yelling, threatening, clenched fists). Action: Use a directive approach with a calm, firm voice. Direct the client to take a time-out, offer PRNs again, and use a "show of force" (4-6 staff members in sight) to indicate that staff will maintain control. Crisis: The client completely loses physical control (hitting, kicking, throwing objects). Action: Intervene physically for safety in a matter-of-fact manner with no bargaining. Use seclusion or restraints with 4-6 trained staff, protect the head, and quickly obtain a provider's order for emergency intramuscular (IM) medications. Recovery: The client regains control and physically relaxes. Action: Encourage the client to discuss their triggers, assist them in relaxing, assess all staff for injuries, and conduct a mandatory staff debriefing. Postcrisis: The client returns to baseline, often displaying remorse or crying. Action: Remove restraints based on behavioral criteria, discuss the event rationally without lecturing, and reintegrate the client into the unit milieu. High-Yield Medications Treating the underlying psychiatric disorder is the primary way to prevent aggression. Acute Agitation: A combination of haloperidol (Haldol) and lorazepam (Ativan) quickly decreases severe agitation and psychotic symptoms. Lorazepam alone is preferred if the agitated patient is not psychotic. Long-Term Management: Lithium treats bipolar aggression. Anticonvulsants (carbamazepine, valproate) manage aggression in dementia, psychosis, and personality disorders. Atypical antipsychotics (clozapine, risperidone) are also highly effective. Always monitor for extrapyramidal side effects, which are swiftly treated with benztropine (Cogentin). Milieu Management & Safety A structured environment with planned activities and consistent 1-on-1 interactions minimizes boredom and prevents aggression. The absolute best predictor of future violence is a prior history of violent behavior. Maintain a safe distance during interactions—potentially violent patients require a body space zone up to four times larger than normal—and never trap the client. Finally, workplace safety requires a code of conduct with zero tolerance for lateral violence (staff bullying), per JCAHO standards.

MH | Eating Disorders

Core Disorders & Distinctions Anorexia Nervosa (AN): Characterized by severe restriction of nutritional intake, extreme fear of weight gain, and severely distorted body image. Clients fail to recognize the illness, have an early onset (ages 14-18), and are significantly underweight. Subtypes include restricting (fasting/exercising) and binge-eating/purging. Bulimia Nervosa (BN): Involves recurrent, secretive binging followed by compensatory behaviors like purging, extreme exercise, or laxative use. Onset is later (ages 18-19), and clients are typically at a normal weight. Unlike AN, clients with BN recognize the pathology and experience immense shame and guilt. High-Yield Medical Complications AN: Amenorrhea, cold sensitivity/lanugo, bradycardia, osteoporosis, and severe electrolyte imbalances (e.g., hypokalemia, hyponatremia). BN: Dental enamel erosion, hypokalemia, hypochloremic alkalosis, and esophageal/gastric erosion. Priority Nursing Assessments & Interventions Safety First: Assess directly for suicidal ideation and self-mutilation, as risk is highly elevated. Milieu & Meal Management: Sit with clients during meals and enforce program limits (e.g., liquid protein for uneaten food). Critically, observe clients for 1 to 2 hours after meals to prevent covert purging. Daily Weights: Weigh clients daily upon awakening after voiding, wearing minimal clothing (hospital gown) to prevent them from hiding objects to artificially inflate weight. Therapeutic Communication: Clients often lack emotional self-awareness (alexithymia) and express emotions somatically. Encourage them to describe feelings using a journal. Never discuss food or deep emotional issues during mealtimes; separate emotions from food. Avoid labeling clients or foods as "good" or "bad". Treatment Modalities & Psychopharmacology AN: The immediate priority is medical stabilization (weight restoration, correcting electrolytes) before psychiatric treatment can begin. Family therapy is highly beneficial for clients under 18. Medications have limited success, though Olanzapine can help with weight gain and bizarre body image distortions. BN: Cognitive-Behavioral Therapy (CBT) is the most effective outpatient treatment. Antidepressants, specifically SSRIs like fluoxetine, are effective in reducing binge eating and improving mood. The "Exam Logic" 20% Focus Priority Action: Address life-threatening medical issues (bradycardia, hypokalemia) and suicide risk first. Milieu Safety: Supervise meals and restrict unsupervised bathroom access to stop the purging cycle. Best Therapeutic Response: Remain empathetic but nonjudgmental; set limits on eating behaviors and focus interactions on strengths unrelated to body size.

MH PHARM | Sertraline

Overview & Mechanism Sertraline is an oral selective serotonin reuptake inhibitor (SSRI) primarily indicated for major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), social anxiety disorder, and premenstrual dysphoric disorder (PMDD). Its therapeutic effect results from selective serotonin reuptake blockade at the neuronal membrane, which directly increases serotonin availability and neural transmission. Administration Guidelines Sertraline may be administered without regard to meals. Capsules must be swallowed whole. The oral liquid solution requires specialized handling: it must be mixed immediately before consumption with exactly 4 ounces of water, ginger ale, lemon-lime soda, lemonade, or orange juice only. The supplied dropper contains dry natural rubber, requiring caution in those with latex sensitivities. Boxed Warnings & Severe Risks Sertraline carries a Boxed Warning regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under 24 years of age. This risk is highest during treatment initiation and following dosage adjustments. Caregivers must vigilantly monitor for clinical worsening or behavioral changes. SSRI use in pediatric patients is also associated with potential growth inhibition, necessitating regular monitoring of height and weight. Other severe adverse reactions include serotonin syndrome, hyponatremia, gastrointestinal bleeding, and QT prolongation. Dosing Framework Depression & OCD: The standard adult starting dose is 50 mg once daily, with a maximum dose of 200 mg/day. In pediatric populations, starting doses range from 12.5 mg to 25 mg daily based on age, gradually titrating while observing a maximum limit of 200 mg/day. Anxiety & PTSD: For panic disorder, PTSD, and social anxiety disorder, the typical adult initiation dose is 25 mg daily, increasing to 50 mg after one week, up to a maximum of 200 mg/day. PMDD: Dosing ranges from 50 to 150 mg daily, administered either continuously throughout the menstrual cycle or strictly during the luteal phase. Off-Label Uses: Includes hot flashes (50-100 mg/day), premature ejaculation (25-50 mg/day), pruritus, and binge-eating disorder. Organ Impairment: For patients with mild hepatic impairment, the daily dose must be reduced by 50%. Use in moderate or severe hepatic impairment is not recommended. Conversely, no dosage adjustments are required for renal impairment. Adverse Effects The most commonly reported adverse effects are mild to moderate, including nausea (26%), diarrhea (20%), insomnia (20%), xerostomia (14%), fatigue (12%), and dizziness (12%). Sexual dysfunction is also highly prominent, presenting as ejaculation dysfunction, erectile dysfunction, and a general decrease in libido. Pharmacokinetics Sertraline undergoes extensive first-pass metabolism in the liver via multiple CYP450 enzymes, primarily CYP2B6. It is highly protein-bound (98%) and exhibits an average elimination half-life of 26 hours. Clinically significant interactions can occur because sertraline inhibits the CYP2D6 isoenzyme in vivo, potentially requiring dose reductions for concurrent medications metabolized by this pathway.

MH PHARM | Paroxetine

Paroxetine: Core Clinical Profile (80/20 Summary) 1. Fundamental Overview & Warnings Paroxetine is an oral selective serotonin reuptake inhibitor (SSRI). It carries a severe Boxed Warning for increasing the risk of suicidal thoughts and behaviors in children, adolescents, and young adults (under 24 years old). It is not FDA-approved for pediatric patients, and chronic use may cause pediatric growth inhibition by suppressing growth hormone secretion. The National Institute for Occupational Safety and Health (NIOSH) classifies it as a hazardous drug, requiring specialized protective equipment (e.g., gloves, protective gowns) during handling, manipulation, or administration. It must not be used during pregnancy due to the risk of teratogenesis. 2. Indications & Administration Paroxetine is indicated for major depression, obsessive-compulsive disorder (OCD), social anxiety disorder, generalized anxiety disorder (GAD), panic disorder, posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and menopausal vasomotor symptoms (hot flashes). It is also utilized off-label for premature ejaculation. Administration: It is given as a single daily dose, typically in the morning. Controlled-release (CR) tablets are enteric-coated and must be swallowed whole without cutting, chewing, or crushing, and should not be co-administered with antacids. Food does not affect bioavailability but can minimize gastrointestinal adverse effects. 3. Core Dosing & Adjustments Adult Dosing: For depression, GAD, and PTSD, the starting immediate-release (IR) dose is 20 mg/day, capped at a maximum of 50 mg/day. For OCD and panic disorder, the target dose is higher at 40 mg/day, with a maximum of 60 mg/day. Menopausal Hot Flashes: A specific 7.5 mg IR capsule is dosed once daily at bedtime. Special Populations: Geriatric patients, as well as those with severe renal (CrCl < 30 mL/min) or hepatic impairment, require lower initial dosing (10 mg/day IR) and have a strict maximum limit of 40 mg/day IR. 4. Pharmacology & CYP450 Interactions Paroxetine blocks neuronal serotonin reuptake, boosting serotonin availability. It requires 1 to 4 weeks of therapy for therapeutic onset due to the delayed down-regulation and desensitization of serotonin autoreceptors. Notably, it possesses the highest anticholinergic activity of all SSRIs. It is 93% to 95% bound to plasma protein. Drug Interactions: Paroxetine is a potent inhibitor of the CYP2D6 isoenzyme. It saturates CYP2D6 early in dosing (within 10-14 days), leading to nonlinear pharmacokinetics, excess drug accumulation, and a shift toward clearance via the CYP3A4 pathway. 5. Primary Adverse Reactions Neurological/Psychiatric: Drowsiness (9-24%), insomnia (8-24%), asthenia (12-22%), headache, and tremor. Severe risks include serotonin syndrome, seizures, and withdrawal symptoms upon rapid cessation. Sexual Dysfunction: Extremely common, featuring ejaculation dysfunction (13-28%), erectile dysfunction (4-10%), and decreased libido. Gastrointestinal & Systemic: Nausea (4-26%), xerostomia/dry mouth (3-18%), hyperhidrosis/sweating (6-11%), constipation, and diarrhea. Other Severe Risks: Hyponatremia/SIADH, bleeding/platelet dysfunction, and bone fractures.

MH PHARM | Venlafaxine

Core Profile and Mechanism Venlafaxine is an oral Serotonin Norepinephrine Reuptake Inhibitor (SNRI) indicated for adult major depressive disorder, generalized anxiety disorder, social anxiety, and panic disorder. It functions by inhibiting the central reuptake of serotonin and norepinephrine, possessing a 30-fold higher affinity for serotonin compared to norepinephrine. The drug is primarily metabolized in the liver via the CYP2D6 enzyme into its major active metabolite, O-desmethylvenlafaxine (ODV). Medications that inhibit CYP2D6 can dangerously elevate venlafaxine plasma concentrations, particularly in CYP2D6 poor metabolizers. Administration and Dosing Standard adult dosing typically begins at 37.5 mg or 75 mg daily. Maximum recommended dosages are generally 225 mg/day for outpatients, though severely depressed hospitalized inpatients may require and tolerate doses up to 375 mg/day. All doses must be taken with food to minimize gastrointestinal side effects. Extended-release capsules must be swallowed whole, or their contents can be sprinkled onto applesauce and swallowed immediately without chewing. Crucially, patients with mild-to-moderate hepatic or renal impairment require total daily dosage reductions ranging from 25% to 50%, while severe organ impairment necessitates reductions of 50% or more. Boxed Warnings and Pediatric Use A critical Black Box Warning highlights an increased risk of suicidal thoughts and behaviors in patients 24 years of age and younger. Venlafaxine's safety and efficacy are not established for children or adolescents under 18. Furthermore, pediatric trials have demonstrated dose-dependent weight loss and significant growth inhibition; therefore, any off-label pediatric use necessitates regular height and weight monitoring. Primary Adverse Reactions The most common mild side effects include nausea (21-58%), headache (25-38%), weight loss, insomnia, dry mouth, dizziness, and sweating. Moderate adverse effects frequently feature sexual dysfunction, such as ejaculation issues (8-19%), decreased libido, and constipation. Because it is an SNRI, venlafaxine can elevate blood pressure and heart rate, and is associated with increased bleeding events. Rare but severe clinical risks include serotonin syndrome, neuroleptic malignant syndrome, gastrointestinal bleeding, QTc prolongation, and Stevens-Johnson syndrome. Off-Label Uses Beyond its primary psychiatric approvals, venlafaxine serves as a first-line non-hormonal therapy for menopausal hot flashes and those associated with breast cancer treatments, effectively utilizing lower doses of 37.5 mg to 75 mg daily. It is also effective for premenstrual dysphoric disorder (PMDD) using continuous or luteal-phase dosing, painful diabetic neuropathy, fibromyalgia, and migraine prophylaxis. According to psychiatric guidelines, it acts as a second-line agent for obsessive-compulsive disorder (OCD) when patients fail initial SSRI therapies. Pharmacokinetics The absolute bioavailability of venlafaxine is approximately 45%. The elimination half-life is 5 hours for the parent drug and 11 hours for the ODV metabolite. Steady-state plasma concentrations are achieved within three days of multiple-dose therapy. Sudden discontinuation of the medication may precipitate early withdrawal symptoms.

MH PHARM | Risperidone

Core Overview & Mechanism Risperidone is an atypical antipsychotic, classified as a serotonin-dopamine antagonist. Its primary efficacy arises from blocking dopamine D2 receptors, which targets the positive symptoms of schizophrenia, and blocking serotonin 5-HT2A receptors, which improves negative symptoms while lowering the risk of extrapyramidal symptoms (EPS) compared to conventional antipsychotics. It also antagonizes alpha-1 and H-1 histamine receptors, which can lead to orthostatic hypotension, sedation, and significant weight gain. The drug and its equally active major metabolite, 9-hydroxyrisperidone, are primarily metabolized by the CYP2D6 enzyme. Boxed Warning Risperidone features a severe boxed warning for elderly patients with dementia-related psychosis, noting a significantly increased risk of morbidity, mortality (typically from heart failure or pneumonia), and cerebrovascular adverse events like stroke. Indications & Standard Dosing Risperidone treats multiple psychiatric conditions, with varied maximum dosages: Schizophrenia: The adult oral target dose is 4 to 8 mg/day (Maximum: 16 mg/day). Bipolar I Disorder: The adult oral target is 1 to 6 mg/day (Maximum: 6 mg/day). Pediatric Uses: It is used to treat irritability in autistic disorder, moderate to severe Tourette's syndrome tics, disruptive behavioral disorders, and pediatric intensive care delirium. Organ Impairment: Patients with hepatic or renal impairment require a lowered starting oral dose (0.5 mg twice daily) and careful, gradual titration. Formulations & Administration Protocols Risperidone's diverse administration routes dictate strict preparation and bridging protocols: Oral: Available as conventional tablets, orally-disintegrating tablets (ODT), and oral solutions. Intramuscular (IM) Depot: Risperdal Consta (gluteal/deltoid) and Rykindo (gluteal only) are dosed every 2 weeks (Maximum: 50 mg). Crucially, IM depots require oral risperidone supplementation during initiation to maintain therapeutic plasma levels (3 weeks for Consta, 1 week for Rykindo). Both involve rigorous reconstitution steps to suspend microspheres in diluent. Subcutaneous (SubQ) Depot: Perseris (monthly) and Uzedy (monthly or bi-monthly) are injected into the abdomen or upper arm. Unlike IM options, SubQ depots do not require oral dosing overlap because they provide clinically relevant concentrations immediately upon administration. Both require highly specific preparation steps, such as mixing liquid and powder syringes for 60 cycles (Perseris) or utilizing forceful downward arm flicks to properly position a viscous air bubble before injection (Uzedy). Key Adverse Reactions & Pharmacokinetics Based on its D2 receptor binding profile, risperidone has a notably higher risk of causing hyperprolactinemia than most other atypical antipsychotics. Severe potential events include tardive dyskinesia, neuroleptic malignant syndrome (NMS), seizures, and suicidality. Moderate to mild side effects prominently include weight gain, pseudoparkinsonism, akathisia, and injection site reactions. Drug clearance relies heavily on renal excretion, with approximately 70% of an oral dose eliminated in the urine.

MH PHARM | Zyprexa

Zyprexa (Olanzapine) 80/20 Summary 1. Mechanism & Profile Zyprexa is an atypical antipsychotic used for major psychiatric conditions. Its efficacy stems from dopamine (D1-D4) and serotonin (5-HT2A) receptor antagonism, modulating central activity to treat positive and negative schizophrenia symptoms. It binds 5-HT2C receptors (regulating food intake), explaining notable weight gain. Binding to muscarinic, histamine H-1, and alpha-1 receptors causes somnolence, orthostatic hypotension, and anticholinergic side effects. 2. Key Indications FDA-approved uses: Schizophrenia & Bipolar I: Monotherapy or maintenance for manic/mixed episodes. Bipolar/Treatment-Resistant Depression: Used jointly with fluoxetine. Acute Agitation: Immediate-release IM injections. Off-label: Chemotherapy-induced nausea/vomiting (CINV) and PICU delirium. 3. Administration Forms Oral: Standard or orally disintegrating tablets; taken without regard to meals. Immediate-Release IM: For agitation. Dissolve in sterile water and inject deeply into the gluteal muscle (max 5 mL per site). Peak plasma concentration is 5 times higher than oral. Extended-Release IM (Zyprexa Relprevv): Depot injection every 2-4 weeks for schizophrenia maintenance. Provides sustained concentrations; half-life is 30 days. 4. Boxed Warnings Post-Injection Delirium/Sedation Syndrome (PDSS): Relprevv carries a strict warning for PDSS if the drug enters the bloodstream rapidly. Must be given in a registered facility. Patients need continuous professional observation for 3+ hours post-injection and an escort home. Elderly with Dementia: Increased mortality risk (heart failure, pneumonia) and cerebrovascular events. Not approved for dementia-related psychosis. Suicidality: Elevated risk of suicidal thoughts in children and young adults. CNS Depression: Impairs cognitive/motor skills, posing a fall risk. Use caution with alcohol/depressants. 5. Pharmacokinetics Extensively metabolized in the liver mainly by CYP1A2, and minimally by CYP2D6. As a major CYP1A2 substrate, concurrent use of inducers (like smoking) increases clearance, requiring dose adjustments. It is 93% protein-bound with an oral half-life of 30 hours. Excreted via urine (57%) and feces (30%). 6. Adverse Reactions Beyond the Boxed Warnings, olanzapine exhibits a wide spectrum of side effects. Common effects involve metabolic disturbances, including hypertriglyceridemia, hypercholesterolemia, hyperglycemia, and increased appetite. Extrapyramidal symptoms, like akathisia and pseudoparkinsonism are also prominent. Severe but rarer reactions include stroke, seizures, neuroleptic malignant syndrome, tardive dyskinesia, and potentially fatal DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

MH | Personality Disorder

Core Concepts Personality disorders (PDs) are enduring, ingrained, maladaptive patterns of behavior and relating to others that severely impair functioning. Diagnosed only after age 18, traits are inflexible, making treatment slow and difficult. Patients rarely recognize their behavior as problematic, often blaming external circumstances. The 3 Diagnostic Clusters Cluster A (Odd/Eccentric): Paranoid (pervasive mistrust/suspicion), Schizoid (detached, unemotional loners), Schizotypal (cognitive distortions, magical thinking, eccentric behavior). Cluster B (Erratic/Dramatic): Antisocial, Borderline, Histrionic (excessive emotionality, attention-seeking), Narcissistic (grandiosity, need for admiration, lack of empathy). Cluster C (Anxious/Fearful): Avoidant (socially inhibited, hypersensitive to rejection), Dependent (excessively submissive, clinging), Obsessive-Compulsive (preoccupied with order, perfection, and mental control). Highest Yield: Borderline Personality Disorder (BPD) Features: Severe instability in mood, self-image, and relationships. Patients exhibit intense impulsivity, fear of abandonment, chronic emptiness, and "splitting" (polarized, all-or-nothing thinking). Nursing Priorities: Patients frequently engage in nonsuicidal self-injury or make suicidal threats. Physical safety is the highest priority; nurses must continually assess suicide risk. Crucial interventions include maintaining strict professional boundaries, minimizing unstructured time with schedules, and teaching cognitive restructuring (thought stopping, positive self-talk, decatastrophizing) to manage dysregulation. Highest Yield: Antisocial Personality Disorder Features: Blatant disregard for the rights of others, deceit, manipulation, impulsivity, and lack of remorse. They often act for personal gain and lack insight. Nursing Priorities: The core action is strict limit setting (state the rule, the consequence, and the expected behavior clearly). Use confrontation to address manipulative behavior in a neutral, nonjudgmental tone. Teach step-by-step problem-solving and the use of time-outs for anger management. Pharmacology & Milieu Management Medications do not cure PDs but target specific symptoms. Aggression and mood dysregulation are treated with lithium, anticonvulsants, or antipsychotics. Chronic anxiety or depression is managed with SSRIs or MAOIs. Patients with BPD and Antisocial PD often attempt "splitting" to divide staff. Consistent team communication and unwavering adherence to the care plan are essential to prevent manipulation and maintain a safe milieu. Nurses must practice self-awareness, as caring for PDs is highly frustrating and can cause burnout; processing emotions with colleagues keeps care objective.

18 di 34